First Indo/Russian Pharma Venture Launched

23 October 1995

The first Indo/Russian joint venture in the field of pharmaceuticals was established during the recent visit to Moscow of India's Commerce Minister, Mr P Chidambaram. The JV is between Dr Reddy's Laboratories of Hyderbad and Russia's Ao-Biomed, a well-known pharmaceutical factory in Russia, with several decades of experience in the manufacture of vaccines, immunologicals and other health care products.

To be called Reddy-Biomed, the JV will manufacture antibiotics and other formulations for the Russian and international markets. During Mr Chidambaram's visit, both countries agreed to set up a sub-group on pharmaceuticals under the working group on Trade and Economic Cooperation, which was decided on in discussions with Russia's Minister of Health, Mr E Nachaev.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight